Share

January 08, 2019; 92 (2) Article

Age and time course of long-term motor and nonmotor complications in Parkinson disease

Stéphane Prange, Teodor Danaila, Chloé Laurencin, Catherine Caire, Elise Metereau, Hélène Merle, Emmanuel Broussolle, Delphine Maucort-Boulch, Stéphane Thobois
First published December 12, 2018, DOI: https://doi.org/10.1212/WNL.0000000000006737
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
262

Share

Article Information

vol. 92 no. 2 e148-e160
DOI: 
https://doi.org/10.1212/WNL.0000000000006737
PubMed: 
30541866
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received May 4, 2018
  • Accepted in final form September 11, 2018
  • First Published December 12, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Disclosures

    1. Stéphane Prange, MD,
    2. Teodor Danaila, MD,
    3. Chloé Laurencin, MD,
    4. Catherine Caire, CRA,
    5. Elise Metereau, PhD,
    6. Hélène Merle, CRA,
    7. Emmanuel Broussolle, MD, PhD,
    8. Delphine Maucort-Boulch, MD, PhD and
    9. Stéphane Thobois, MD, PhD
  1. Stéphane Prange, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Fondation pour la Recherche M?dicale (research grant FRM-FDM 40482); (2) France Parkinson

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Teodor Danaila, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Abbvie

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. France Parkinson

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Chloé Laurencin, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. abbvie, funding for travel to a congress saint jude and homeperf funding for travel to a congress

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Catherine Caire, CRA,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Elise Metereau, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Hélène Merle, CRA,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Emmanuel Broussolle, MD, PhD,
    8. Scientific Advisory Boards:

    1. Served on the French scientific advisory boards for Schwarz Pharma (2002-2006), Eutherapy (2005), Boehringer- Ingelheim (2004-2011), GE-Health Care (2004-2007), Lundbeck (2009-on going), UCB Pharma (2010-on going) and Novartis Pharma (2005-2015), ABBVIE (2015-2018)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Received funding for a trip and congress registration from Novartis Pharma (2005, 2010, 2011, 2013), GSK (2009), Boehringer-Ingelheim (2006,2007,2008), TEVA (2013), Medtronic (2013),UCB (2018)

    Editorial Boards:

    1. Serve as an editorial board member of European Neurology (2004-on going) and Revue Neurologique (Paris) (2009-on going)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Aguettantlaboratories

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Delphine Maucort-Boulch, MD, PhD and
    9. Scientific Advisory Boards:

    1. (1) DSMB for the company Maat Pharma in the past 2 years

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Nephrology Dialysis Transplantation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Stéphane Thobois, MD, PhD
    10. Scientific Advisory Boards:

    1. Commercial entity : Novartis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Non-Profit entity: Movement Disorders Society teaching courseProfit entity: TEVA,Zambon, Abbvie,Aguettant, Lundbeck, UCB, Novartis : Honoraria for speaking engagements, travel

    Editorial Boards:

    1. European Journal of Neurology, associate editor, 2009-2012Journal of Neurodegenerative Diseases, associate editor, 2012-2017Movement Disorders: editor, 2015-2017

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. medtronic

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Commercial entity: medtronic

    Research Support, Government Entities:

    1. (1) Sponsor/funding source, grant number(s), role, year(s):National PHRC 2014, Subthalamic nucleus deep brain stimulation for severe dystonia associated with Wilson?s disease. PI(2) ANR 2010, ANR-09-MNPS-018, Co-PI.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) 2011, Fondation pour la Recherche M?dicale, R?le de la dopamine et de la s?rotonine dans l?expression des signes non moteurs et des m?canismes de compensation au stade pr?coce de la maladie de parkinson. Co-PI(2) 2010, Association France Parkinson. Hypersexuality in Parkinson's disease: fMRI study. Co-PI(3) Fondation pour la recherche medicale. Thesis grant for stephane prange 2016(4) France Parkinson 2017. Role de la serotonine dans les troubles du controle des impulsions dans la maladie de Parkinson.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From Université Lyon (S.P., T.D., C.L., E.M., E.B., S.T.), Institut des Sciences Cognitives–Marc Jeannerod, CNRS, UMR 5229, Bron; Hospices Civils de Lyon (S.P., T.D., C.C., C.L., E.M., H.M., E.B., S.T.), Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson, Bron; Université Lyon (C.L., E.B., D.M.-B., S.T.), Faculté de Médecine Lyon Sud Charles Mérieux, Oullins; Hospices Civils de Lyon (D.M.-B.), Service de Biostatistique, Lyon; and Université Lyon (D.M.-B.), Laboratoire de Biométrie et Biologie Évolutive, CNRS, UMR 5558, Pierre Benite, France.
  1. Correspondence
    Dr. Prange stephane.prange{at}isc.cnrs.fr
View Full Text

Article usage

Article usage: December 2018 to December 2019

AbstractFullPdfSource
Dec 2018599044Highwire
Jan 2019146415990Highwire
Feb 20192583022Highwire
Mar 20193371714Highwire
Apr 2019167158Highwire
May 2019121710Highwire
Jun 2019125611Highwire
Jul 201910069Highwire
Aug 2019100812Highwire
Sep 201960411Highwire
Oct 20191241117Highwire
Nov 20199567Highwire
Dec 20198367Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me